These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7882335)

  • 21. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
    Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
    J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
    Costello JF; Berger MS; Huang HS; Cavenee WK
    Cancer Res; 1996 May; 56(10):2405-10. PubMed ID: 8625319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas.
    Xu L; Sgroi D; Sterner CJ; Beauchamp RL; Pinney DM; Keel S; Ueki K; Rutter JL; Buckler AJ; Louis DN
    Cancer Res; 1994 Oct; 54(20):5262-4. PubMed ID: 7923151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Loss of CDKN2 gene and amplification of cyclin D1 gene in human esophageal cancer].
    Zheng J; Hou P; Zhou C
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):408-11. PubMed ID: 9387288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
    Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
    Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector.
    Jin X; Nguyen D; Zhang WW; Kyritsis AP; Roth JA
    Cancer Res; 1995 Aug; 55(15):3250-3. PubMed ID: 7614457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
    He J; Allen JR; Collins VP; Allalunis-Turner MJ; Godbout R; Day RS; James CD
    Cancer Res; 1994 Nov; 54(22):5804-7. PubMed ID: 7954404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p16 and p16 beta are potent growth suppressors of head and neck squamous carcinoma cells in vitro.
    Liggett WH; Sewell DA; Rocco J; Ahrendt SA; Koch W; Sidransky D
    Cancer Res; 1996 Sep; 56(18):4119-23. PubMed ID: 8797577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines.
    Hirama T; Miller CW; Wilczynski SP; Koeffler HP
    Mod Pathol; 1996 Jan; 9(1):26-31. PubMed ID: 8821952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for u.v. induction of CDKN2 mutations in melanoma cell lines.
    Pollock PM; Yu F; Qiu L; Parsons PG; Hayward NK
    Oncogene; 1995 Aug; 11(4):663-8. PubMed ID: 7651729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
    Srivenugopal KS; Ali-Osman F
    Oncogene; 1996 May; 12(9):2029-34. PubMed ID: 8649864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines.
    Liu Q; Neuhausen S; McClure M; Frye C; Weaver-Feldhaus J; Gruis NA; Eddington K; Allalunis-Turner MJ; Skolnick MH; Fujimura FK
    Oncogene; 1995 Dec; 11(11):2455. PubMed ID: 8570198
    [No Abstract]   [Full Text] [Related]  

  • 33. Adenoviral p16/CDKN2 gene transfer to malignant glioma: role of p16 in growth, invasion, and senescence.
    Kim SK; Wang KC; Cho BK; Lim SY; Kim YY; Oh CW; Chung YN; Kim CY; Lee CT; Kim HJ
    Oncol Rep; 2003; 10(5):1121-6. PubMed ID: 12883667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
    Harada H; Nakagawa K; Iwata S; Saito M; Kumon Y; Sakaki S; Sato K; Hamada K
    Cancer Res; 1999 Aug; 59(15):3783-9. PubMed ID: 10446996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
    Barrett MT; Sanchez CA; Galipeau PC; Neshat K; Emond M; Reid BJ
    Oncogene; 1996 Nov; 13(9):1867-73. PubMed ID: 8934532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors.
    Lubomierski N; Kersting M; Bert T; Muench K; Wulbrand U; Schuermann M; Bartsch D; Simon B
    Cancer Res; 2001 Aug; 61(15):5905-10. PubMed ID: 11479232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system.
    Wang Y; Becker D
    Oncogene; 1996 Mar; 12(5):1069-75. PubMed ID: 8649798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
    Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
    Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16INK4A, MTS1) gene and other loci on human chromosome 9.
    Wu Q; Possati L; Montesi M; Gualandi F; Rimessi P; Morelli C; Trabanelli C; Barbanti-Brodano G
    Int J Cancer; 1996 Mar; 65(6):840-6. PubMed ID: 8631601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
    Herman JG; Jen J; Merlo A; Baylin SB
    Cancer Res; 1996 Feb; 56(4):722-7. PubMed ID: 8631003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.